1. Home
  2. UTHR vs DUOL Comparison

UTHR vs DUOL Comparison

Compare UTHR & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • DUOL
  • Stock Information
  • Founded
  • UTHR 1996
  • DUOL 2011
  • Country
  • UTHR United States
  • DUOL United States
  • Employees
  • UTHR N/A
  • DUOL N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • DUOL Computer Software: Prepackaged Software
  • Sector
  • UTHR Health Care
  • DUOL Technology
  • Exchange
  • UTHR Nasdaq
  • DUOL Nasdaq
  • Market Cap
  • UTHR 20.7B
  • DUOL 13.3B
  • IPO Year
  • UTHR 1999
  • DUOL 2021
  • Fundamental
  • Price
  • UTHR $470.12
  • DUOL $184.30
  • Analyst Decision
  • UTHR Buy
  • DUOL Buy
  • Analyst Count
  • UTHR 12
  • DUOL 17
  • Target Price
  • UTHR $495.08
  • DUOL $331.67
  • AVG Volume (30 Days)
  • UTHR 568.9K
  • DUOL 2.3M
  • Earning Date
  • UTHR 10-29-2025
  • DUOL 11-05-2025
  • Dividend Yield
  • UTHR N/A
  • DUOL N/A
  • EPS Growth
  • UTHR 16.08
  • DUOL 338.81
  • EPS
  • UTHR 26.38
  • DUOL 8.04
  • Revenue
  • UTHR $3,128,400,000.00
  • DUOL $964,271,000.00
  • Revenue This Year
  • UTHR $13.68
  • DUOL $38.90
  • Revenue Next Year
  • UTHR $5.63
  • DUOL $25.89
  • P/E Ratio
  • UTHR $17.68
  • DUOL $23.03
  • Revenue Growth
  • UTHR 13.50
  • DUOL 39.86
  • 52 Week Low
  • UTHR $266.98
  • DUOL $182.00
  • 52 Week High
  • UTHR $479.50
  • DUOL $544.93
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 67.39
  • DUOL 22.23
  • Support Level
  • UTHR $444.04
  • DUOL $182.59
  • Resistance Level
  • UTHR $464.27
  • DUOL $203.77
  • Average True Range (ATR)
  • UTHR 15.76
  • DUOL 12.39
  • MACD
  • UTHR 1.66
  • DUOL -7.85
  • Stochastic Oscillator
  • UTHR 84.40
  • DUOL 1.80

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About DUOL Duolingo Inc.

Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.

Share on Social Networks: